Physicians ID Barriers to 'No Antibiotic' Strategy for Pediatric Viral Pneumonia
18 Jan 2024
THURSDAY, Jan. 18, 2024 -- There are considerable barriers relating to implementation of a "no antibiotic" strategy for mild community-acquired pneumonia (CAP) in children, according to a study published online Jan. 18 in Pediatrics.
Julia E. Szymczak, Ph.D., from the University of Utah School of Medicine in Salt Lake City, and colleagues conducted semistructured interviews to identify barriers to the implementation of a no antibiotic strategy for mild CAP in young children. Respondents included 18 parents of young children diagnosed with mild CAP in the previous three years and 20 clinicians practicing in outpatient settings.
The researchers found that none of the parents had heard of the no antibiotic strategy, with varying support for the strategy. Their degree of support was related to the desire to avoid unnecessary medications, trust in clinicians, emotional difficulties relating to caring for a sick child, desire for relief from suffering, willingness to accept the risks associated with unnecessary antibiotics, and judgment relating to the severity of illness. Overall, 55 percent of the clinicians were familiar with the no antibiotic strategy. Diagnostic uncertainty, consequences of undertreatment, parental expectations, follow-up concerns, and acceptance of the risks associated with unnecessary antibiotic treatment for many children in order to avoid adverse outcomes for some children were challenges in not using antibiotics.
"Although advances in diagnostic testing and increasing evidence for the safety of the no antibiotics strategy will likely improve clinicians' confidence in avoiding antibiotics in young children with mild CAP, it will not be sufficient to change current practice because of the social, emotional, and logistical challenges," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.